Intestine Cancer Therapeutics Market Report 2026

The intestine cancer therapeutics market size has grown strongly in recent years. It will grow from $15.12 billion in 2025 to $16.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising incidence of colorectal and small intestine cancers, increased awareness of digestive system cancers, advancements in chemotherapy and surgical techniques, expansion of hospital-based oncology services, improved cancer screening programs.

The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $22.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing investment in oncology research, rising demand for targeted cancer therapies, expansion of personalized cancer treatment approaches, improved survival outcomes driving long-term treatment demand. Major trends in the forecast period include increasing adoption of combination cancer therapies, growing focus on early-stage cancer treatment, rising use of multimodal treatment approaches, expansion of specialized oncology treatment centers, improved patient access to advanced cancer care.

The rising prevalence of hereditary colorectal cancer syndromes is expected to drive the growth of the intestine cancer therapeutics market in the coming years. Hereditary colorectal cancer syndromes are a set of genetic conditions that elevate an individual's likelihood of developing colorectal cancer (cancer of the colon or rectum). These syndromes play a crucial role in intestinal cancer therapeutics by providing insights into specific genetic mutations that significantly increase the risk of colorectal cancer. For example, in July 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that by 2040, the prevalence of hereditary colorectal cancer is expected to rise considerably, with an estimated 3.2 million new cases and 1.6 million deaths annually. This reflects a 63% increase in new cases and a 73% rise in fatalities compared to current figures. Consequently, the growing prevalence of hereditary colorectal cancer syndromes is fueling the expansion of the intestine cancer therapeutics market.

Major companies in the intestine cancer therapeutics market are focusing on developing innovative products such as Lonsurf and obtaining approvals to reach larger patient populations, drive sales, and increase revenue. LONSURF is a combination of two drugs, trifluridine and tipiracil, designed for treating adult patients with metastatic colorectal cancer. For example, in August 2023, Taiho Oncology Inc., a US-based pharmaceutical company, received approval for Lonsurf from the US Food and Drug Administration. Lonsurf is administered as a single oral tablet. Trifluridine works by inhibiting the growth of cancer cells, while tipiracil extends the effectiveness of trifluridine by preventing its breakdown in the body. The approval of Lonsurf offers patients with metastatic colorectal cancer and other eligible cancers a new treatment option that may improve outcomes and quality of life.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer intends to strengthen its oncology therapeutics portfolio by incorporating Seagen’s innovative antibody-drug conjugate (ADC) technologies, which are being studied across various solid tumors, including HER2-positive metastatic colorectal cancer. Seagen Inc. is a US-based biotechnology company focused on targeted cancer medicines, particularly advanced ADC platforms used to develop novel treatments for colorectal and other solid tumors.

Major companies operating in the intestine cancer therapeutics market are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited.

Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intestine cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the intestine cancer therapeutics market by increasing costs of imported oncology drugs, biologics, and advanced manufacturing inputs used in cancer treatment. These impacts are most evident in immunotherapy and targeted therapy segments, particularly across asia-pacific and europe where reliance on global pharmaceutical supply chains is high. Higher tariffs have raised treatment costs for hospitals and specialty centers. However, tariffs are also encouraging domestic drug manufacturing, local production of biologics, and supply chain diversification, supporting long-term market stability.

The intestine cancer therapeutics market research report is one of a series of new reports that provides intestine cancer therapeutics market statistics, including intestine cancer therapeutics industry global market size, regional shares, competitors with a intestine cancer therapeutics market share, detailed intestine cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the intestine cancer therapeutics industry. This intestine cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intestine cancer therapeutics encompass the various treatment options available for small intestine and colorectal cancers that impact the digestive system. These treatments are designed to eliminate or control cancerous cells and enhance patient outcomes. The specific treatment approach depends on the cancer stage, the patient’s overall health, and other relevant factors.

The primary types of treatments for intestine cancer therapeutics include immunotherapy, chemotherapy, and others. Immunotherapy is a cancer treatment that leverages the body’s immune system to target and destroy cancer cells. These treatments are distributed through multiple channels, including hospital pharmacies, online pharmacies, and retail pharmacies, serving hospitals, homecare, specialty centers, and other healthcare settings.

The intestine cancer therapeutics market includes revenues earned by entities by provide services such as colonoscopies and fecal occult blood tests, clinical trials, supportive care, genetic testing and counseling, and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestine cancer therapeutics market also includes sales of Alymsys, Avastin (bevacizumab), bevacizumab, Camptosar (irinotecan hydrochloride), capecitabine, cetuximab, angiogenesis inhibitors, multikinase inhibitors, epigenetic agents, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.